Carsten Utoft Niemann
20052023

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Expertises

Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL). Investigator-initiated, inter-group studies in CLL (Nordic CLL study group, the HOVON (the Netherlands) and the GCLLSG (Germany) study groups), MRD testing and biobanking for MCL studies (Nordic Lymphoma group). Genetic and functional characterization of primary CLL cells (collaboration with NIH and DFCI), Machine learning algorithms and epidemiology (collaboration with PERSIMUNE, SSI and DTU).

"

Main research areas

CLL is a malignancy of antigen reactive, mature B cells involving blood, bone marrow, and lymphoid tissues and is the most common leukemia in Western countries with a very heterogeneous clinical course. By molecular and genetic characterization of primary CLL cells and application of machine-learning iterations to identify big data patterns within the generated data in combination with demographic, paraclinical, , microbial, and clinical parameters to develop tailored CLL-specific treatment and supportive care at the individual patient level.

Current research

With the B-cell receptor pathway as the core, my group has been part of a paradigm shift for treatment of CLL with novel targeted therapies developed also for patients with the most dismal outcome due to TP53 aberrations. With the parallel development of translational and experimental studies based on our own unique CLL biobank, CLL epidemiology studies based on the comprehensive Danish National CLL database, and CLL clinical inter-group trials, we have created a unique position for development of not only prognostic algorithms but also tailored novel treatment regimens, which can be prospectively validated via investigator-initiated clinical trials.

Potential conflicts of interest

Research funding from the Danish Cancer Society, Novo Nordisk Foundation, Arvid Nilssons Foundation, Rigshospitalet, Abbvie and Persimune. Clinical research collaboration: Roche, Novartis, Janssen, Abbvie.Consultancies, travel grants: Roche, Abbvie, Janssen, Novartis, Gilead

Fingerprint

Dive into the research topics where Carsten Utoft Niemann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
  • Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Mansouri, L., Thorvaldsdottir, B., Sutton, L-A., Karakatsoulis, G., Meggendorfer, M., Parker, H., Nadeu, F., Brieghel, C., Laidou, S., Moia, R., Rossi, D., Catherwood, M., Kotaskova, J., Delgado, J., Rodríguez-Vicente, A. E., Benito, R., Rigolin, G. M., Bonfiglio, S., Scarfo, L., Mattsson, M., & 41 othersDavis, Z., Gogia, A., Rani, L., Baliakas, P., Foroughi-Asl, H., Jylhä, C., Skaftason, A., Rapado, I., Miras, F., Martinez-Lopez, J., de la Serna, J., Rivas, J. M. H., Thornton, P., Larráyoz, M. J., Calasanz, M. J., Fésüs, V., Mátrai, Z., Bödör, C., Smedby, K. E., Espinet, B., Puiggros, A., Gupta, R., Bullinger, L., Bosch, F., Tazón-Vega, B., Baran-Marszak, F., Oscier, D., Nguyen-Khac, F., Zenz, T., Terol, M. J., Cuneo, A., Hernández-Sánchez, M., Pospisilova, S., Mills, K., Gaidano, G., Niemann, C. U., Campo, E., Strefford, J. C., Ghia, P., Stamatopoulos, K. & Rosenquist, R., Feb 2023, 1 p.

    Research output: Other contributionResearch

  • Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naïve unfit CLL without TP53 aberrations

    Slot, M., Niemann, C. U., Ehlers, L. H. & Rotbain, E. C., 15 May 2023, (E-pub ahead of print) In: Blood advances.

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Mansouri, L., Thorvaldsdottir, B., Sutton, L-A., Karakatsoulis, G., Meggendorfer, M., Parker, H., Nadeu, F., Brieghel, C., Laidou, S., Moia, R., Rossi, D., Catherwood, M., Kotaskova, J., Delgado, J., Rodríguez-Vicente, A. E., Benito, R., Rigolin, G. M., Bonfiglio, S., Scarfo, L., Mattsson, M., & 41 othersDavis, Z., Gogia, A., Rani, L., Baliakas, P., Foroughi-Asl, H., Jylhä, C., Skaftason, A., Rapado, I., Miras, F., Martinez-Lopez, J., de la Serna, J., Rivas, J. M. H., Thornton, P., Larráyoz, M. J., Calasanz, M. J., Fésüs, V., Mátrai, Z., Bödör, C., Smedby, K. E., Espinet, B., Puiggros, A., Gupta, R., Bullinger, L., Bosch, F., Tazón-Vega, B., Baran-Marszak, F., Oscier, D., N'Guyen-Khac, F., Zenz, T., Terol, M. J., Cuneo, A., Hernández-Sánchez, M., Pospisilova, S., Mills, K., Gaidano, G., Niemann, C. U., Campo, E., Strefford, J. C., Ghia, P., Stamatopoulos, K. & Rosenquist, R., Feb 2023, In: Leukemia. 37, 2, p. 339-347 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  • First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Nösslinger, T., Janssens, A., & 31 othersChristiansen, I., Baumann, M., Frederiksen, H., van der Klift, M., Jäger, U., Leys, M. B. L., Hoogendoorn, M., Lotfi, K., Hebart, H., Gaska, T., Koene, H., Enggaard, L., Goede, J., Regelink, J. C., Widmer, A., Simon, F., De Silva, N., Fink, A-M., Bahlo, J., Fischer, K., Wendtner, C-M., Kreuzer, K. A., Ritgen, M., Brüggemann, M., Tausch, E., Levin, M-D., van Oers, M., Geisler, C., Stilgenbauer, S., Hallek, M. & GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland, 11 May 2023, In: The New England journal of medicine. 388, 19, p. 1739-1754 16 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  • High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

    Fürstenau, M., Thus, Y. J., Robrecht, S., Mellink, C. H. M., van der Kevie-Kersemaekers, A-M. F., Dubois, J., von Tresckow, J., Patz, M., Gregor, M., Thornton, P., Staber, P. B., Tadmor, T., Levin, M-D., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Janssens, A., Christiansen, I., & 27 othersNoesslinger, T., Baumann, M., Hebart, H., Gaska, T., Regelink, J., Dompeling, E. C., Lindstrom, V., Juliusson, G., Widmer, A. A., Goede, J. S., Goldschmidt, N., Simon, F., De Silva, N., Fink, A. M., Fischer, K., Wendtner, C-M., Ritgen, M., Brüggemann, M., Tausch, E., Spaargaren, M., Eldering, E., Stilgenbauer, S., Niemann, C. U., Hallek, M., Eichhorst, B., Kreuzer, K-A. & Kater, A. P., 12 May 2023, (E-pub ahead of print) In: Blood.

    Research output: Contribution to journalJournal articleResearchpeer-review